Results 201 to 210 of about 196,135 (282)

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Weight stigma in Latin America and the Caribbean: a call to action. [PDF]

Lancet Reg Health Am
Flint SW, Vila T.
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Strengthening access to antihypertensive medicines through HEARTS in the Americas: the Grenada experience. [PDF]

Rev Panam Salud Publica
Renaud-Thomas KA, Mark L, Isaac C, Malcolm T, Charles S.   +4 more
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Population Structure of the Invasive Asian Tiger Mosquito, <i>Aedes albopictus</i>, in the Americas. [PDF]

Insects
Corley MK, Cosme LV, Armbruster PA, Reilly PF, Martins AJ, Medley K, Alfonso-Parra C, Barron DG, Gloria-Soria A, Micieli MV, Pohlenz T, Soghigian J, Verna TN, Wang X, Westby KM, Yan G, Caccone A.   +16 more
europepmc   +1 more source

Optimization of seminal extracellular vesicle isolation protocols for cancer biomarker analysis using proteomic profiling

Molecular Oncology, EarlyView.
This paper shows that size‐exclusion chromatography and sequential centrifugation applied to seminal plasma enrich for different populations of extracellular vesicles. This may significantly affect the detection and analysis of extracellular vesicle‐associated cancer biomarkers.
Elen Telumyan, Beatriz Martín‐Gracia, Eva Bassols‐Citores, Krizia Sagini, Maria K. Andersen, Tuula A. Nyman, May‐Britt Tessem, Morten B. Rye, Alicia Llorente   +8 more
wiley   +1 more source

Lessons from the Bundibugyo outbreak for the Americas. [PDF]

Lancet Reg Health Am
Garrett DO, Martin RM.
europepmc   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Vitamin D for type 2 diabetes prevention: cost-effective, but not yet cost-saving. [PDF]

Lancet Reg Health Am
Zhang J, Zhan X, Li T.
europepmc   +1 more source